Manufacturer named-patient programs

What this page is about

This page exists because manufacturer named-patient programs is a recurring question for patients, families, and physicians working through cross-border specialty-drug access. The material here is oriented toward the practical decisions that fall out of that question — not abstract policy. For case-specific questions, the right starting point is always the treating physician.

How this fits the broader landscape

Cross-border access to specialty medicines runs on a three-legged stool: a legitimate destination-country pathway (Named Patient Program, personal import, or an equivalent mechanism); a DSCSA-provenanced US supply chain from a licensed specialty wholesaler; and a treating physician who is accountable for the clinical decision and the patient’s monitoring. The topic on this page touches one or more of those legs.

What we see in practice

In our day-to-day coordination work, the most common sources of avoidable delay on topics like this are documentation completeness, mismatched expectations between what the patient wants and what the destination-country pathway permits, and supply-chain assumptions that do not match what DSCSA-compliant sourcing actually looks like. Most of these can be de-risked with a short upfront conversation between the treating physician and a pharmacist.

Practical next steps

If the topic on this page is relevant to a specific patient case, the useful next step is a short intake at reservemeds.com/request. Our clinical team returns a feasibility note within one business day, with the destination-country posture, an expected timeline, and a pricing range. If the topic is background reading rather than a specific case, the articles linked at the bottom of this page are the best next reads.

What Reserve Meds does and does not do

We are a US-licensed specialty-pharmacy service that coordinates source-country sourcing, DSCSA documentation, and cold-chain logistics for Named Patient Program and personal-import pathways. We do not replace the treating physician, do not offer medical advice for a specific patient, do not source controlled substances, and do not operate in gray-market channels. Where a case falls outside what we can do compliantly, we say so.

Further reading

See our articles index for the full library, our country pages for jurisdiction-specific posture, and our pathways index for the mechanisms our work runs on.

Start a request

Start a request